CD8A and neoplasm: The anti-tumor response elicited by R848 is characterized by the formation of tertiary lymphoid structures, increased CD8+ T-cell infiltration with evidence of increased activation and cytotoxicity, and decreased Treg concentration, all of which are associated with improved prognosis in human malignancy23–25.